Corvus Pharmaceuticals enters its third-quarter report with a balance sheet that looks nothing like it did a year ago and a stock price that suggests the market has stopped giving it credit for that. Management used the last call to project confidence, citing clean Phase 1 atopic dermatitis data, a fresh pile of cash and a pipeline spreading into new diseases. Since then, the shares have fallen 18.5% while the S&P 500 was essentially flat. That gap makes this quarter less about the loss per share and more about whether the company's operating promises are arriving on schedule.

Wall Street expects a loss of $0.21 per share, a bit wider than the $0.19 loss last quarter and well beyond the $0.12 loss a year ago. That 75% deterioration is the expected cost of running several trials at once, not a sign of trouble. Last quarter, R&D roughly doubled from the prior year to about $16 million and the net loss reached about $18 million. A figure near consensus would show spending holding steady after that step-up. A sharply larger loss would raise questions about how fast the burn is accelerating. Without revenue, the key financial number is cash. Corvus held $215.2 million at the end of June after raising about $189 million in its follow-on offering. That supports management's runway guidance into the second quarter of 2028, a major extension from the late-2026 runway it was citing only a few quarters earlier. Reaffirming that runway as spending climbs would be the most direct proof that the financing truly de-risked the story.

The operating checklist is specific. Management said the Phase 1b hidradenitis suppurativa study of soqualitinib would begin in September with 25 patients at 200mg twice daily. The asthma Phase 2, notable for enrolling both T2 and non-T2 patients and roughly doubling the addressable population, was also guided for the second half of 2026. Confirmation that both studies are dosing patients would show that pipeline breadth is more than slideware. The China partnership through ANGEL is the nearest data catalyst, with cohort-one atopic dermatitis results promised before year-end. Any sign that those results are slipping into 2027 would be hard to dismiss, since timing drift is already the weak spot in this narrative.

That weak spot centers on the Phase 3 PTCL trial. The interim futility analysis moved from late 2026 to the first quarter of 2027, and management noted that this event-driven timeline could move again. Phase 2 atopic dermatitis topline data also shifted from mid-2027 to the third quarter of 2027. Neither delay is alarming alone, but a third would start to look like a pattern. Holding both dates steady, along with progress on the expected Blood publication of Phase 1 PTCL results, would help rebuild trust in the company's timelines.

Sentiment has edged from modestly bearish ahead of last quarter to barely bullish now, which suggests a cautious rather than hostile mood. The chart tells a harsher story. At $10.52, the stock sits well below its 200-day moving average of $14.37 and close to the $9.21 low of its post-earnings range. It has also slipped below the floor of the prior quarter's range. Expectations are clearly not inflated, so a report that simply delivers on schedule could look better than the share price implies.

The central question is whether Corvus can turn last quarter's confidence into visible execution. That means new trials enrolling, the China readout on track, PTCL timing unchanged and a cash runway that still reaches into 2028 despite rising costs. If those pieces hold, the selloff looks like impatience. Another round of delays would suggest the market's skepticism was justified.